 |
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. |
GenomeDx Presents Data on Prostate Cancer Test's Prognostic Performance, Impact on Treatment
February 20, 2013
GenomeDx Presents Data on Prostate Cancer Test's Prognostic Performance, Impact on Treatment
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Prostate Cancer MDx Firm GenomeDx to Launch First Test This Year
January 18, 2013 / GenomeWeb Daily News - TCGA Study Shows Molecular Subtypes May Better Stratify Endometrial Cancer Patients than Histology
May 1, 2013 / Pharmacogenomics Reporter - GenomeDx, Mayo Clinic Expand Research Deal
April 29, 2013 / GenomeWeb Daily News - Prostate Cancer Risk Markers Show Promise for Test to ID Elevated Risk in Men with Benign Hyperplasia
April 3, 2013 / Pharmacogenomics Reporter - Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter